CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 26 enrolled
Drug / intervention
LY900014 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02636361
NCT02636361Phase 1Completed
CompareCT.gov

Pharmacokinetics, Glucodynamics, Safety, and Tolerability of Multiple LY900014 Formulations

Eli Lilly and Company·interventional·Posted Dec 21, 2015·Updated May 13, 2020

In Brief

A Phase 1 clinical trial evaluating LY900014 and Insulin lispro (Humalog) for Healthy. Completed, enrolled 26 participants across 1 site.

Detailed Summary

This study will evaluate how quickly the body absorbs, breaks down, and gets rid of the different formulations of LY900014. This study will determine how the different formulations, when injected under the skin, will affect the blood sugar levels in the body, and how safe it is.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsHealthy
CountriesSingapore
Collaborators--

Timeline

Phase 1CompletedFinished
20162017201820192020202120222023202420252026
First PostedDec 21, 2015
Enrollment StartDec 1, 2015
Primary CompletionFeb 1, 2016
TodayJul 2, 2026
Enrollment to primary: 2 monthsPosted 10.5 years ago

Interventions

LY900014drug

Administered subcutaneously (SC)

Insulin lispro (Humalog)drug

Administered SC